# Other Events

## Filter by content:

### Types
- MGUS
- Newly diagnosed multiple myeloma
- Relapsed/refractory multiple myeloma
- Smoldering multiple myeloma

### Therapeutics
- Auto-HSCT
- Bortezomib
- CAR therapy
- Carfilzomib
- CC-93269
- Cevostamab
- Ciltacabtagene autoleucel
- Cyclophosphamide
- Daratumumab  
- Dexamethasone
- Elranatamab
- Etentamig
- Forimtamig
- Iberdomide
- Idecabtagene vicleucel
- Lenalidomide
- Linvoseltamab
- Mezigdomide
- OriCAR-017
- Pavurutamab
- T-cell engagers
- Talquetamab
- Teclistamab

### Congresses
- 2021 Symposium
- 2022 Symposium
- 2023 Hub event
- 2024 Symposium
- ASH 2020
- COMy 2020
- COMy 2021
- EBMT 2020
- EBMT 2021
- EHA 2023
- EHA 2024
- ESH 2020
- SOHO 2020

### Trials
- ALCYONE
- APOLLO
- ASCENT
- CANDOR
- CARTITUDE-1
- CARTITUDE-5
- CARTITUDE-6
- CASTORE
- 3A06
- FORTE
- GEM-CESAR
- GRIFFIN
- ICARIA-MM
- IFM2009
- IKEMA
- KarMMa
- KarMMa-9
- LINKER-MM1
- MagnetisMM-3
- MAIA
- MajesTEC-1
- MM-014
- MonumenTAL-1
- POLLUX
- PROMISE
- QUINTESSENTIAL
- QUREDEX
- RedirecTT-1

### Expert Opinions
- Amrita Krishnan
- Barry Quinn
- Bruno Paiva
- Doris Hansen
- Flaminia Coluzzi
- Heinz Ludwig
- Irene Ghobrial
- Krina Patel
- María-Victoria Mateos
- Michael Hudecek
- Mohamad Mohty
- Naresh Bumma
- Noopur Raje
- Sagar Lonial
- Sergio Giralt
- Shaji Kumar
- Vincent Rajkumar

### Educational Resources
- Multiple Myeloma Hub symposiums
- Risk scores and prognostic tools
- Special populations

---

## Key Events
1. **[The next wave of immune-based therapies: What you need to know in relapsed/refractory multiple myeloma](/content/medical-information/symposium-or-the-next-wave-of-immune-based-therapies-what-you-need-to-know/index.html)**  
     
   Date: Aug 14, 2024

2. **[How to sequence CAR T-cell therapy and bispecific antibodies in relapsed/refractory multiple myeloma](/content/medical-information/symposium-or-how-to-sequence-car-t-cell-therapy-and-bispecific-antibodies-in-relapsedrefractory-multiple-myeloma/index.html)**  
     
   Date: Aug 12, 2024

3. **[Looking to the future of bispecific antibodies in MM, and panelist Q&A](/content/medical-information/symposium-or-looking-to-the-future-of-bispecific-antibodies-in-mm-and-panelist-qanda/index.html)**  
     
   Date: Apr 9, 2024

4. **[Practical management of adverse events with immunotherapies](/content/medical-information/symposium-or-practical-management-of-adverse-events-with-immunotherapies/index.html)**  
     
   Date: Apr 9, 2024

5. **[Beyond BCMA: Novel strategies using bispecific antibodies](/content/medical-information/symposium-or-beyond-bcma-novel-strategies-using-bispecific-antibodies/index.html)**  
     
   Date: Apr 9, 2024

6. **[Answering the common challenges facing real-world CAR T-cell therapies](/content/medical-information/answering-the-common-challenges-facing-real-world-car-t-cell-therapies/index.html)**  
     
   Date: Jul 26, 2023

7. **[Real-world patient cases: CAR T-cell therapy](/content/medical-information/real-world-patient-cases-car-t-cell-therapy/index.html)**  
     
   Date: Jul 24, 2023

8. **[Implementing a holistic pain treatment plan in advanced multiple myeloma](/content/medical-information/implementing-a-holistic-pain-treatment-plan-in-advanced-multiple-myeloma/index.html)**  
     
   Date: Dec 8, 2022

9. **[Biomarkers and patient eligibility for CAR T-cell therapies in MM](/content/medical-information/biomarkers-and-patient-eligibility-for-car-t-cell-therapies-in-mm/index.html)**  
     
   Date: Jul 21, 2023

10. **[Management of pain: Understanding the current needs of patients with multiple myeloma](/content/medical-information/management-of-pain-understanding-the-current-needs-of-patients-with-multiple-myeloma/index.html)**  
      
    Date: Mar 31, 2022

---